2 June 2021
Effective of June 1st, 2021, the Chinese Patent Law has been amended and here are the key highlights of the Amendments.
The Fourth Amendments of the Chinese Patent Law comes into effect as of today, June 1st, 2021.
We have summarised and compiled the key highlights of the Amendments our Principal & Head of China Patent Group, Li Mi, has previously covered. We hope you find this information useful on the related subject matters below.
-
Rouse – Fourth Amendment of China’s Patent Law – Impact on Design Patents
-
Rouse – New amendments to the Chinese Patent Law will impact the pharmaceutical industry
Prefer to hear directly from our experts? Tune into Doug Clark's latest webcast series IP Snacks covering the Recent Amendments to the Chinese Patent Law.
Join us for our upcoming webinar on IP Arbitration in Asia – Risks, Opportunities, Rewards.
Online – 11:30am ET
The past decade has seen rapid growth in the arbitration of Intellectual Property disputes in Asia, particularly in relation to China. In addition to contractual disputes over technology transfer or licensing some parties are also electing to resolve infringement disputes through arbitration rather than engage in expensive multi-jurisdictional litigation.
Arbitration is also the preferred method of dispute resolution for cases involving China because foreign judgments are not enforceable there. While the Chinese courts are an option – and despite the substantial improvement in the Chinese IP litigation system – many parties prefer to arbitrate dispute rather than litigate.
The COVID-19 pandemic has seen intense cooperation efforts in the pharmaceutical and life sciences areas as well as significant leaps in the development and use of technology, all of which may in the longer term lead to disputes over the scope and terms of the cooperation agreements and rights to inventions and other developments.
Rouse’s Global Head of Dispute Resolution, Doug Clark, will talk about how he sees the future of IP dispute resolution in Asia, focussing on China, as well as the various options for arbitration IP disputes in Asia. In doing so he will discuss key issues that have arisen in recent arbitration disputes he has handled both as an arbitrator and as counsel.
Arbitration is also the preferred method of dispute resolution for cases involving China because foreign judgments are not enforceable there. While the Chinese courts are an option – and despite the substantial improvement in the Chinese IP litigation system – many parties prefer to arbitrate dispute rather than litigate.
The COVID-19 pandemic has seen intense cooperation efforts in the pharmaceutical and life sciences areas as well as significant leaps in the development and use of technology, all of which may in the longer term lead to disputes over the scope and terms of the cooperation agreements and rights to inventions and other developments.
Rouse’s Global Head of Dispute Resolution, Doug Clark, will talk about how he sees the future of IP dispute resolution in Asia, focussing on China, as well as the various options for arbitration IP disputes in Asia. In doing so he will discuss key issues that have arisen in recent arbitration disputes he has handled both as an arbitrator and as counsel.
Please click here to register. This is a free to attend webinar.
For further information, please contact:
Douglas Clark, Principal,
Global Head of Dispute Resolution, Rouse
Global Head of Dispute Resolution, Rouse
dclark@rouse.com
